CD274 and glioma: A key player in this context is the upregulation of programmed cell death ligand 1 (PD-L1) expression in gliomas post-treatment, which subsequently triggers immune suppression and impairs CAR-T cell function through the PD-1/PD-L1 signaling axis [13, 14].